Literature DB >> 19726617

Antibodies induced by dengue virus type 1 and 2 envelope domain III recombinant proteins in monkeys neutralize strains with different genotypes.

Lidice Bernardo1, Osmel Fleitas, Alequis Pavón, Lisset Hermida, Gerardo Guillén, Maria G Guzman.   

Abstract

In the present work, we evaluated the neutralizing capacity of the antibodies induced by dengue virus type 1 and 2 envelope domain III recombinant proteins in monkeys against strains of different dengue virus type 1 and 2 genotypes. Here we demonstrated that dengue virus type 1 and 2 recombinant proteins induced high titers of neutralizing antibodies against different genotype strains.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19726617      PMCID： PMC2786379          DOI： 10.1128/CVI.00191-09

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  27 in total

1.  The fusion site of envelope fragments from each serotype of Dengue virus in the P64k protein, influence some parameters of the resulting chimeric constructs.

Authors:  Aída Zulueta; Lisset Hermida; Laura Lazo; Iris Valdés; Rayner Rodríguez; Carlos López; Ricardo Silva; Delfina Rosario; Jorge Martín; María G Guzmán; Gerardo Guillén
Journal:  Biochem Biophys Res Commun       Date:  2003-08-29       Impact factor: 3.575

2.  Localization of a neutralizing epitope on the envelope protein of dengue virus type 2.

Authors:  B Lin; C R Parrish; J M Murray; P J Wright
Journal:  Virology       Date:  1994-08-01       Impact factor: 3.616

3.  Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence.

Authors:  K Hiramatsu; M Tadano; R Men; C J Lai
Journal:  Virology       Date:  1996-10-15       Impact factor: 3.616

4.  The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution.

Authors:  F A Rey; F X Heinz; C Mandl; C Kunz; S C Harrison
Journal:  Nature       Date:  1995-05-25       Impact factor: 49.962

5.  Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization.

Authors:  D M Morens; S B Halstead; P M Repik; R Putvatana; N Raybourne
Journal:  J Clin Microbiol       Date:  1985-08       Impact factor: 5.948

6.  Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants.

Authors:  S C Kliks; S Nimmanitya; A Nisalak; D S Burke
Journal:  Am J Trop Med Hyg       Date:  1988-03       Impact factor: 2.345

7.  Dengue virus structural differences that correlate with pathogenesis.

Authors:  K C Leitmeyer; D W Vaughn; D M Watts; R Salas; I Villalobos; C Ramos; R Rico-Hesse
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

8.  Effect of dengue-1 antibodies on American dengue-2 viral infection and dengue haemorrhagic fever.

Authors:  Tadeusz J Kochel; Douglas M Watts; Scott B Halstead; Curtis G Hayes; Angelica Espinoza; Vidal Felices; Roxana Caceda; Christian T Bautista; Ysabel Montoya; Susan Douglas; Kevin L Russell
Journal:  Lancet       Date:  2002-07-27       Impact factor: 79.321

9.  Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates.

Authors:  Lidice Bernardo; Alienys Izquierdo; Mayling Alvarez; Delfina Rosario; Irina Prado; Carlos López; Rafael Martínez; Jorge Castro; Emidalys Santana; Lisset Hermida; Gerardo Guillen; María G Guzmán
Journal:  Antiviral Res       Date:  2008-07-03       Impact factor: 5.970

10.  Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection.

Authors:  B M Kaufman; P L Summers; D R Dubois; K H Eckels
Journal:  Am J Trop Med Hyg       Date:  1987-03       Impact factor: 2.345
View more
  8 in total

1.  Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates.

Authors:  Sean P McBurney; Justine E Sunshine; Sarah Gabriel; Jeremy P Huynh; William F Sutton; Deborah H Fuller; Nancy L Haigwood; William B Messer
Journal:  Vaccine       Date:  2016-04-13       Impact factor: 3.641

2.  The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2.

Authors:  Lázaro Gil; Ernesto Marcos; Alienys Izquierdo; Laura Lazo; Iris Valdés; Peris Ambala; Lucy Ochola; Rikoi Hitler; Edith Suzarte; Mayling Álvarez; Prisilla Kimiti; James Ndung'u; Thomas Kariuki; María Guadalupe Guzmán; Gerardo Guillén; Lisset Hermida
Journal:  Immunol Cell Biol       Date:  2014-09-02       Impact factor: 5.126

3.  Simplifying complex sequence information: a PCP-consensus protein binds antibodies against all four Dengue serotypes.

Authors:  David M Bowen; Jessica A Lewis; Wenzhe Lu; Catherine H Schein
Journal:  Vaccine       Date:  2012-07-31       Impact factor: 3.641

4.  Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope.

Authors:  S Kyle Austin; Kimberly A Dowd; Bimmi Shrestha; Christopher A Nelson; Melissa A Edeling; Syd Johnson; Theodore C Pierson; Michael S Diamond; Daved H Fremont
Journal:  PLoS Pathog       Date:  2012-10-04       Impact factor: 6.823

5.  Autophagy-associated dengue vesicles promote viral transmission avoiding antibody neutralization.

Authors:  Yan-Wei Wu; Clément Mettling; Shang-Rung Wu; Chia-Yi Yu; Guey-Chuen Perng; Yee-Shin Lin; Yea-Lih Lin
Journal:  Sci Rep       Date:  2016-08-25       Impact factor: 4.379

Review 6.  Recent Developments in Recombinant Protein-Based Dengue Vaccines.

Authors:  Nagesh K Tripathi; Ambuj Shrivastava
Journal:  Front Immunol       Date:  2018-08-23       Impact factor: 7.561

7.  A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III.

Authors:  Dan Hu; Zhongyu Zhu; Shun Li; Yongqiang Deng; Yanling Wu; Nana Zhang; Vinita Puri; Chunyu Wang; Peng Zou; Cheng Lei; Xiaolong Tian; Yulu Wang; Qi Zhao; Wei Li; Ponraj Prabakaran; Yang Feng; Jane Cardosa; Chengfeng Qin; Xiaohui Zhou; Dimiter S Dimitrov; Tianlei Ying
Journal:  PLoS Pathog       Date:  2019-06-26       Impact factor: 6.823

Review 8.  Utility, limitations, and future of non-human primates for dengue research and vaccine development.

Authors:  Carlos A Sariol; Laura J White
Journal:  Front Immunol       Date:  2014-09-24       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.